Business
CORRECTION FROM SOURCE: CardioComm Solutions Completes HeartCheck(TM) Clinical Validation for Long-Term, Self-Managed, Remote Monitoring of Atrial Fibrillation Patients Post-Ablation
This document corrects and replaces the press release that was issued by CardioComm Solutions,...
About this update from Cardiocomm Solutions, Inc.
[{"type":"text","content":"CORRECTION FROM SOURCE: CardioComm Solutions Completes HeartCheck(TM) Clinical Validation for Long-Term, Self-Managed, Remote Monitoring of Atrial Fibrillation Patients Post-AblationHeartCheck(TM) ECG PEN and ECG Handheld Monitor used for routine in-home arrhythmia monitoringThis document corrects and replaces the press release that was issued by CardioComm Solutions, Inc. (\"CardioComm\" or the \"Company\"), today, August 13, 2018 at 12:53PM EST. The error occurred in the headline where it should have read \"Clinical\" instead of \"Clincial\".Toronto, Ontario--(Newsfile Corp. - August 13, 2018) - CardioComm Solutions, Inc. (TSXV: EKG) (\"CardioComm\" or the \"Company\"), a leading global provider of consumer heart monitoring and electrocardiogram (\"ECG\") acquisition and management software solutions, confirms its HeartCheck™ device and GEMS™ software technologies have moved into routine clinical use following completion of a long-term, remote arrhythmia monitoring pilot in high risk patients.Partners in Advanced Cardiac Evaluation (\"PACE\") is a physician directed medical practice specializing in cardiology services and patient care within the Province of Ontario (Canada). PACE cardiologists have been prescribing use of the HeartCheck™ ECG PEN and ECG Handheld Monitor to their patients to provide up to one year of enhanced remote patient monitoring (\"RPM\") for arrhythmias in addition to use of conventional but term-limited Holter and event monitoring. Atrial Fibrillation (\"AF\") is a life threatening arrhythmia that is difficult to detect and to treat. Cardiac ablation is a procedure commonly used to correct heart rhythm problems like AF; however, it is possible for AF to recur as early as two months after ablation in 30% to 50% of treated patients (Calkins et al 1547-5271/2017 HRS). Serious and life threatening post-ablation recurrent arrhythmias such as AF can be \"silent\", and occur without any symptoms, discomfort or warning. Having access to patient's ECGs on a daily basis allows physician to better monitor the re-occurrence of AF as objectively as possible. This speaks to the need for a reliable method for post-ablation arrhythmia monitoring that can provide a reliable patient-management solution without an added work burden to clinics. This monitoring also qualifies for health care reimburseme...